Pulmonary hemorrhage and exogenous surfactant therapy: A metaanalysis

The Journal of Pediatrics

Volumn 123, Issue 4, 1993, Pages 603-610

  Raju, Tonse N K ^a,b   Langenberg, Patricia ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SURFACTANT;

ARTICLE; HUMAN; INCIDENCE; LUNG HEMORRHAGE; META ANALYSIS; NEWBORN; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RISK ASSESSMENT;

HEMORRHAGE; HUMAN; INCIDENCE; INFANT, NEWBORN; LUNG DISEASES; PULMONARY SURFACTANTS; REGRESSION ANALYSIS; RESPIRATORY DISTRESS SYNDROME; RISK FACTORS;

EID: 0027368774     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(05)80963-1     Document Type: Article

References (41)

1. The surfactant era—starting off right [Editorial]
2. Surfactant replacement therapy in respiratory distress syndrome: meta-analysis of clinical trials of single-dose surfactant extracts
3. Beta blockade during and after myocardial infarction: an overview of the randomized trials
4. A comparison of statistical methods for combining event rates from clinical trials
5. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of synthetic surfactant
6. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial
7. Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams
8. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome
9. A controlled atrial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome
10. Initial Clinical trial of Exosurf, a protein-free, synthetic surfactant for the prophylaxis and early treatment of hyaline membrane disease
11. Prophylactic treatment of very premature infants with human surfactant
12. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome
13. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials
14. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome
15. Controlled trial of artificial surfactant to prevent respiratory distress syndrome
16. Two controlled trials of dry artificial surfactant: early effects and later outcome in babies with surfactant deficiency
17. Ten center trial of artificial surfactant (artificial lung expanding compound) in very premature babies
18. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial
19. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants
20. Surfactant replacement therapy at birth: final analysis if a clinical trial and comparisons with similar trials
21. Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome
22. Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: a multicenter controlled clinical trial
23. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment
24. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lungimmaturity
25. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized, prospective clinical trial
26. Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease
27. Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease
28. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial
29. A multicenter randomized placebo-controlled trial of surfactant therapy for respiratory distress syndrome
30. A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants
31. Exogenous surfactant for treatment of respiratory distress syndrome in premature infants
32. A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome
33. Single versus multipledose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome
34. Biased inferences in tests for average partial associations
35. Exosurf treatment investigational new drug phase: effect of an individualized third dose in infants with respiratory distress syndrome
36. Early versus delayed neonatal administration of a synthetic surfactant—the judgement of OSIRIS
37. Treatment investigational new drug experience with Survanta (beractant)
38. Artificial surfactant therapy in hyaline membrane disease
39. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: an autopsy evaluation
40. Retrospective search for bleeding diathesis among premature infants with pulmonary hemorrhage after synthetic surfactant treatment
41. Stable microbubble test for predicting the risk of respiratory distress syndrome. I. Comparison with other predictors of fetal lung maturity inamniotic fluid